Biology subjects

Saba, K. H.

Publications and source records attributed to Saba, K. H..

3 recordsLinked to original sources

bioRxiv2026

Genetic profiling of soft tissue and bone tumors using SarcDBase

To streamline molecular profiling of tumor biopsies, we developed SarcDBase, an openly accessible tool that extracts and interprets clinically relevant genetic alterations from next-generation sequencing data. By automatically linking identified variants to curated, user-defined reference lists, SarcDBase minimizes the need for specialized expertise and reduces the burden of manual data processing. The platform delivers detailed molecular profiles, diagnostic insights and an intuitive interface for comprehensive interpretation. SarcDBases performance was evaluated in a heterogeneous cohort of 204 deep-sequenced bone and soft tissue tumors. In most cases (81%), its interpretation closely matched the curated post-sequencing diagnosis. Discrepancies mainly occurred in samples lacking diagnostically informative mutations. In some instances, SarcDBase flagged rare or unexpected alterations, including previously unreported gene fusions. This highlights SarcDBases dual potential as both an interrogative research tool and facilitator of molecular diagnostics, especially for reclassification of diagnostically challenging tumor types.

genomics↗

bioRxiv2024

CDK4 is co-amplified with either TP53 promoter gene fusions or MDM2 through distinct mechanisms in osteosarcoma

Amplification of the MDM2 and CDK4 genes on chromosome 12 is commonly associated with low-grade osteosarcomas. In this study, we conducted high-resolution genomic and transcriptomic analyses on 33 samples from 25 osteosarcomas, encompassing both high- and low-grade cases with MDM2 and/or CDK4 amplification. We identified four major subgroups: (i) low-grade osteosarcoma with chromosome 12 amplicons as the sole acquired alteration, (ii) high- and low-grade tumours with CDK4 and MDM2 amplification along with few changes affecting other chromosomes, (iii) high-grade osteosarcomas with heavily rearranged genomes including either CDK4 and MDM2 amplification or (iv) CDK4 amplification and TP53 structural alterations. The amplicons involving MDM2 exhibited signs of an initial chromothripsis event affecting chromosome 12. In contrast, there was no indication of a chromothripsis event on chromosome 12 in TP53-rearranged cases. Instead, the initial disruption of the TP53 locus resulted in breakage and repair processes that co-amplified the CDK4 locus. Furthermore, our investigation revealed recurring promoter swapping events that involved the regulatory regions of the FRS2, PLEKHA5, and TP53 genes. These events led to the ectopic expression of partner genes, with the ELF1 gene being upregulated by the FRS2 and TP53 promoter regions, respectively, in two distinct cases.

cancer biology↗

bioRxiv2020

Oncogenes hijack a constitutively active TP53 promoter in osteosarcoma

How massive genome rearrangements confer a competitive advantage to a cancer cell has remained an enigma. The malignant bone tumour osteosarcoma harbours an extreme number of structural variations and thereby holds the key to understand complex cancer genomes. Genome integrity in osteosarcoma is generally lost together with disruption of normal TP53 gene function, the latter commonly through either missense mutations or structural alterations that separate the promoter region from the coding parts of the gene. To unravel the consequences of a TP53 promoter relocated in this manner, we performed in-depth genetic analyses of osteosarcoma biopsies (n=148) and cell models. We show that TP53 structural variations are early events that not only facilitate further chromosomal alterations, but also allow the TP53 promoter to upregulate genes erroneously placed under its control. Paradoxically, many of the induced genes are part of the TP53-associated transcriptome, suggesting a need to counterbalance loss of TP53 function through separation-of-function mutations via promoter swapping. Our findings demonstrate how massive genome errors can functionally turn the promoter region of a tumour suppressor gene into a constitutively active oncogenic driver.

cancer biology↗